The U.S. Food and Drug Administration (FDA) recently approved Aimmune Therapeutics’ Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp] for children suffering from peanut allergy.
Palforzia is intended to help “allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanuts” for children between the ages of 4 and 17, but these children are advised to continue to avoid peanuts in their daily diets.
Peter Marks, MD, PhD, the director of the FDA’s Center for Biologics Evaluation and Research comments on the approval: “Peanut allergy affects approximately 1 million children in the U.S. and only 1 out of 5 of these children will outgrow their allergy. Because there is no cure, allergic individuals must strictly avoid exposure to prevent severe and potentially life-threatening reactions…Even with strict avoidance, inadvertent exposures can and do occur. When used in conjunction with peanut avoidance, Palforzia provides an FDA-approved treatment option to help reduce the risk of these allergic reactions in children with peanut allergy.”
Please read more about the approval here.
